{"protocolSection": {"identificationModule": {"nctId": "NCT00667992", "orgStudyIdInfo": {"id": "D5252C00008"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma", "officialTitle": "A Phase 3, Randomised, Open-label, Crossover Study to Compare HFA vs CFC pMDI Formulations of Budesonide on Methacholine Hyper-reactivity in Patients With Stable, Persistent, Mild to Moderate Asthma"}, "statusModule": {"statusVerifiedDate": "2012-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-23", "studyFirstSubmitQcDate": "2008-04-27", "studyFirstPostDateStruct": {"date": "2008-04-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-12", "resultsFirstSubmitQcDate": "2012-10-09", "resultsFirstPostDateStruct": {"date": "2012-11-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-10-09", "lastUpdatePostDateStruct": {"date": "2012-11-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC. Budesonide HFA has been already given in other research studies, in both healthy volunteers and subjects with asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma hyperreactivity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 99, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Budesonide Hydrofluoroalkane (HFA) 100", "type": "ACTIVE_COMPARATOR", "description": "Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks", "interventionNames": ["Drug: Budesonide HFA"]}, {"label": "Budesonide HFA 400", "type": "ACTIVE_COMPARATOR", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks", "interventionNames": ["Drug: Budesonide HFA"]}, {"label": "Budesonide Chlorofluorocarbon (CFC) 100", "type": "ACTIVE_COMPARATOR", "description": "Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks", "interventionNames": ["Drug: Budesonide CFC"]}, {"label": "Budesonide CFC 400", "type": "ACTIVE_COMPARATOR", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks", "interventionNames": ["Drug: Budesonide CFC"]}], "interventions": [{"type": "DRUG", "name": "Budesonide HFA", "description": "standard daily inhaled dose", "armGroupLabels": ["Budesonide HFA 400", "Budesonide Hydrofluoroalkane (HFA) 100"]}, {"type": "DRUG", "name": "Budesonide CFC", "description": "standard daily inhaled dose", "armGroupLabels": ["Budesonide CFC 400", "Budesonide Chlorofluorocarbon (CFC) 100"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)", "description": "Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%.\n\nThe ratio of Methacholine concentration measured at 2 weeks to that at Baseline.", "timeFrame": "Baseline and week 2"}], "secondaryOutcomes": [{"measure": "Peak Exploratory Flow (PEF)", "description": "Change in PEF at Week 2 from baseline, mean over all days in run-in and all dasy in treatment period, with baseline as covariate.", "timeFrame": "Baseline to week 2 recorded daily"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second)", "description": "FEV1 change from baseline", "timeFrame": "Baseline to week 2"}, {"measure": "FEF 25-75 (Forced Expiratory Flow 25-75)", "description": "FEF 25-75- Forced expiratory flow over the middle one half of the FVC. The results are expressed as the change from baseline", "timeFrame": "Baseline and week 2"}, {"measure": "eNO (Exhaled Nitrogen Oxide)", "description": "eNO ratio of baseline", "timeFrame": "baseline and week 2"}, {"measure": "Asthma Symptom Score Morning", "description": "Asthma Symptom score recorded daily in the morning: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the morning is presented.", "timeFrame": "2 weeks"}, {"measure": "Asthma Symptom Score Evening", "description": "Asthma Symptom score recorded daily in the evening: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the evening is presented.", "timeFrame": "2 weeks"}, {"measure": "Asthma Symptom Score Total", "description": "Asthma Symptom score recoded daily, Total. Scale: 0 - 3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily is presented.", "timeFrame": "2 weeks"}, {"measure": "Rescue Medication Morning", "description": "The average of means for inhalations of rescue medication in the morning is presented.", "timeFrame": "2 weeks"}, {"measure": "Rescue Medication Evening", "description": "The average of means for inhalations of rescue medication in the evening is presented.", "timeFrame": "2 weeks"}, {"measure": "Rescue Medication Total", "description": "The average of means for inhalations of rescue medication in morning and evening combined over a 24 hour period is presented.", "timeFrame": "2 weeks"}, {"measure": "Peak Exploratory Flow (PEF) Morning", "description": "Peak Exploratory Flow (PEF) recorded daily in the morning", "timeFrame": "2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients suffering from stable, persistent, mild to moderate asthma as defined by Global Initiative for Asthma (GINA) Guidelines and for whom FEV1 \\> 60 %\n* ICS taking \u2264 1000 \u03bcg BDP per day, or equivalent\n* Methacholine PC20 \\< 4 mg/mL\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to budesonide or any other constituents of the budesonide HFA pMDI or budesonide CFC pMDI.\n* Currently a smoker or who has ceased smoking within 6 months of Visit 1.\n* Exacerbations of asthma requiring oral steroids, hospitalisation or change in asthma therapy in the previous three months.\n* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Brian Lipworth, PhD, MD", "affiliation": "Asthma and Allergy Research Group Division of Medicine and Therapeutics Ninewells Hospital and Medical School University of Dundee", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "King of Prussia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.08927, "lon": -75.39602}}, {"facility": "Research Site", "city": "Dundee", "state": "Scotland", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "Research Site", "city": "Perth", "state": "Scotland", "country": "United Kingdom", "geoPoint": {"lat": 56.39522, "lon": -3.43139}}]}, "referencesModule": {"references": [{"pmid": "28065396", "type": "DERIVED", "citation": "Anderson WJ, Short PM, Jabbal S, Lipworth BJ. Inhaled corticosteroid dose response in asthma: Should we measure inflammation? Ann Allergy Asthma Immunol. 2017 Feb;118(2):179-185. doi: 10.1016/j.anai.2016.11.018. Epub 2017 Jan 3."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "144 were enrolled, 45 were excluded: 11 for eligibility not fulfilled, 8 with condition under investigation worsened, 8 for voluntary withdrawal, 17 with reasons not specified, and 1 lost to follow-up and 99 were randomised.", "groups": [{"id": "FG000", "title": "Budesonide Hydrofluoroalkane (HFA) First, Then Budesonide CFC", "description": "Budesonide Hydrofluoroalkane (HFA), 100 mcg twice daily followed by Budesonide HFA 400 mcg twice daily First, Wash out, then Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily."}, {"id": "FG001", "title": "Budesonide Chlorofluorocarbon (CFC) First, Then Budesonide HFA", "description": "Budesonide CFC, 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily First, Wash out, then Budesonide HFA 100 mcg twice daily followed by 400 mcg twice daily."}], "periods": [{"title": "First Intervention 100 Mcg Twice Daily", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Condition Under Investigation Worsened", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Second Intervention 400 Mcg Twice Daily", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Condition Under Investigation Worsened", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Medication not allowed taken", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Wash-out", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Not within one doubling dilution", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Failure to wash-out", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Third Intervention 100 Mcg Twice Daily", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Forth Intervention 400 Mcg Twice Daily", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "35"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Budesonide Hydrofluoroalkane (HFA) First, Then Budesonide CFC", "description": "Budesonide Hydrofluoroalkane (HFA), 100 mcg twice daily followed by Budesonide HFA 400 mcg twice daily, First then Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily."}, {"id": "BG001", "title": "Budesonide Chlorofluorocarbon (CFC) First, Then Budesonide HFA", "description": "Budesonide CFC, 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily First, then Budesonide HFA 100 mcg twice daily followed by 400 mcg twice daily."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "89"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.0", "lowerLimit": "19.0", "upperLimit": "65.0"}, {"groupId": "BG001", "value": "39.5", "lowerLimit": "18.0", "upperLimit": "64.0"}, {"groupId": "BG002", "value": "39.75", "lowerLimit": "18.0", "upperLimit": "65.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "50"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "39"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)", "description": "Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%.\n\nThe ratio of Methacholine concentration measured at 2 weeks to that at Baseline.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline and week 2", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane (HFA) 100", "description": "Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon(CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.546", "lowerLimit": "1.343", "upperLimit": "1.780"}, {"groupId": "OG001", "value": "2.163", "lowerLimit": "1.877", "upperLimit": "2.494"}, {"groupId": "OG002", "value": "1.673", "lowerLimit": "1.449", "upperLimit": "1.928"}, {"groupId": "OG003", "value": "2.079", "lowerLimit": "1.801", "upperLimit": "2.401"}]}]}]}, {"type": "SECONDARY", "title": "Peak Exploratory Flow (PEF)", "description": "Change in PEF at Week 2 from baseline, mean over all days in run-in and all dasy in treatment period, with baseline as covariate.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters/minutes", "timeFrame": "Baseline to week 2 recorded daily", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane (HFA) 100", "description": "Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon(CFC) 100", "description": "Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.7", "lowerLimit": "3.9", "upperLimit": "15.6"}, {"groupId": "OG001", "value": "12.7", "lowerLimit": "6.8", "upperLimit": "18.6"}, {"groupId": "OG002", "value": "12.0", "lowerLimit": "6.1", "upperLimit": "17.9"}, {"groupId": "OG003", "value": "9.1", "lowerLimit": "3.2", "upperLimit": "15.1"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second)", "description": "FEV1 change from baseline", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline to week 2", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "lowerLimit": "0.05", "upperLimit": "0.11"}, {"groupId": "OG001", "value": "0.10", "lowerLimit": "0.07", "upperLimit": "0.13"}, {"groupId": "OG002", "value": "0.10", "lowerLimit": "0.07", "upperLimit": "0.13"}, {"groupId": "OG003", "value": "0.11", "lowerLimit": "0.08", "upperLimit": "0.14"}]}]}]}, {"type": "SECONDARY", "title": "FEF 25-75 (Forced Expiratory Flow 25-75)", "description": "FEF 25-75- Forced expiratory flow over the middle one half of the FVC. The results are expressed as the change from baseline", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters/seconds", "timeFrame": "Baseline and week 2", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.005", "upperLimit": "0.17"}, {"groupId": "OG001", "value": "0.14", "lowerLimit": "0.08", "upperLimit": "0.20"}, {"groupId": "OG002", "value": "0.15", "lowerLimit": "0.09", "upperLimit": "0.21"}, {"groupId": "OG003", "value": "0.20", "lowerLimit": "0.13", "upperLimit": "0.26"}]}]}]}, {"type": "SECONDARY", "title": "eNO (Exhaled Nitrogen Oxide)", "description": "eNO ratio of baseline", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "baseline and week 2", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "lowerLimit": "0.62", "upperLimit": "0.70"}, {"groupId": "OG001", "value": "0.57", "lowerLimit": "0.53", "upperLimit": "0.60"}, {"groupId": "OG002", "value": "0.66", "lowerLimit": "0.63", "upperLimit": "0.70"}, {"groupId": "OG003", "value": "0.59", "lowerLimit": "0.55", "upperLimit": "0.62"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score Morning", "description": "Asthma Symptom score recorded daily in the morning: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the morning is presented.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon(CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.39", "lowerLimit": "0.34", "upperLimit": "0.44"}, {"groupId": "OG001", "value": "0.29", "lowerLimit": "0.24", "upperLimit": "0.34"}, {"groupId": "OG002", "value": "0.39", "lowerLimit": "0.34", "upperLimit": "0.44"}, {"groupId": "OG003", "value": "0.30", "lowerLimit": "0.25", "upperLimit": "0.35"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score Evening", "description": "Asthma Symptom score recorded daily in the evening: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the evening is presented.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.48", "lowerLimit": "0.43", "upperLimit": "0.52"}, {"groupId": "OG001", "value": "0.32", "lowerLimit": "0.27", "upperLimit": "0.38"}, {"groupId": "OG002", "value": "0.46", "lowerLimit": "0.41", "upperLimit": "0.50"}, {"groupId": "OG003", "value": "0.36", "lowerLimit": "0.31", "upperLimit": "0.41"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score Total", "description": "Asthma Symptom score recoded daily, Total. Scale: 0 - 3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily is presented.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "lowerLimit": "0.78", "upperLimit": "0.96"}, {"groupId": "OG001", "value": "0.61", "lowerLimit": "0.52", "upperLimit": "0.71"}, {"groupId": "OG002", "value": "0.85", "lowerLimit": "0.76", "upperLimit": "0.94"}, {"groupId": "OG003", "value": "0.66", "lowerLimit": "0.56", "upperLimit": "0.76"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Morning", "description": "The average of means for inhalations of rescue medication in the morning is presented.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of inhalations", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane (HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.71", "lowerLimit": "0.60", "upperLimit": "0.82"}, {"groupId": "OG001", "value": "0.45", "lowerLimit": "0.34", "upperLimit": "0.56"}, {"groupId": "OG002", "value": "0.62", "lowerLimit": "0.51", "upperLimit": "0.73"}, {"groupId": "OG003", "value": "0.50", "lowerLimit": "0.39", "upperLimit": "0.61"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Evening", "description": "The average of means for inhalations of rescue medication in the evening is presented.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of inhalations", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane(HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "lowerLimit": "0.77", "upperLimit": "1.03"}, {"groupId": "OG001", "value": "0.67", "lowerLimit": "0.52", "upperLimit": "0.80"}, {"groupId": "OG002", "value": "0.84", "lowerLimit": "0.71", "upperLimit": "0.97"}, {"groupId": "OG003", "value": "0.64", "lowerLimit": "0.50", "upperLimit": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Total", "description": "The average of means for inhalations of rescue medication in morning and evening combined over a 24 hour period is presented.", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of inhalations/24 hours", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane (HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon(CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.58", "lowerLimit": "1.35", "upperLimit": "1.80"}, {"groupId": "OG001", "value": "1.10", "lowerLimit": "0.86", "upperLimit": "1.33"}, {"groupId": "OG002", "value": "1.39", "lowerLimit": "1.16", "upperLimit": "1.62"}, {"groupId": "OG003", "value": "1.05", "lowerLimit": "0.81", "upperLimit": "1.29"}]}]}]}, {"type": "SECONDARY", "title": "Peak Exploratory Flow (PEF) Morning", "description": "Peak Exploratory Flow (PEF) recorded daily in the morning", "populationDescription": "Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters/minutes", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Budesonide Hydrofluoroalkane (HFA) 100", "description": "Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks"}, {"id": "OG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks"}, {"id": "OG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "426", "lowerLimit": "421", "upperLimit": "431"}, {"groupId": "OG001", "value": "437", "lowerLimit": "433", "upperLimit": "442"}, {"groupId": "OG002", "value": "428", "lowerLimit": "424", "upperLimit": "433"}, {"groupId": "OG003", "value": "438", "lowerLimit": "433", "upperLimit": "442"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Budesonide Hydrofluoroalkane (HFA) 100", "description": "Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 86, "otherNumAffected": 0, "otherNumAtRisk": 86}, {"id": "EG001", "title": "Budesonide HFA 400", "description": "Budesonide HFA 400 mcg twice daily for 2 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 81, "otherNumAffected": 0, "otherNumAtRisk": 81}, {"id": "EG002", "title": "Budesonide Chlorofluorocarbon (CFC) 100", "description": "Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 85, "otherNumAffected": 0, "otherNumAtRisk": 85}, {"id": "EG003", "title": "Budesonide CFC 400", "description": "Budesonide CFC 400 mcg twice daily for 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 79, "otherNumAffected": 0, "otherNumAtRisk": 79}], "seriousEvents": [{"term": "Oral Candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRa 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Lower Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRa 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 79}]}, {"term": "Respiratory Tract Infection Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRa 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 79}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M18666", "name": "Methacholine Chloride", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}